Reported Earlier, Apellis Wins FDA Approval For EMPAVELI To Treat Rare Kidney Diseases C3G And IC-MPGN With 68% Proteinuria Reduction

+3.05% Pre

Apellis Pharmaceuticals

APLS

25.31

25.21

+3.05%

-0.40% Pre

Proven efficacy across all three key markers of disease—68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 deposits
Broad label includes adults and adolescents with C3G or primary IC-MPGN, and post-transplant C3G disease recurrence
Well-established safety profile, consistent across >2,200 patient years in approved indications
C3G and primary IC-MPGN are rare kidney diseases with high risk of kidney failure

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.